Japan Approves GSK's COVID-19 Drug
Newsfrom JapanPolitics Lifestyle
Tokyo, Sept. 27 (Jiji Press)--Japanese health minister Norihisa Tamura Monday approved British pharmaceutical company GlaxoSmithKline PLC's drug to treat COVID-19 patients who are not severely ill.
His approval of sotrovimab, made under fast-track procedures, came after a health ministry expert panel gave the go-ahead earlier the same day.
Sotrovimab is the second approved COVID-19 drug in Japan for patients with mild to moderate symptoms after antibody cocktail Ronapreve, which is sold by Chugai Pharmaceutical Co. <4519>.
It is the fifth authorized coronavirus medicine in the country, including drugs to treat severely ill patients.
Sotrovimab, a monoclonal antibody to attack the virus, is administered by intravenous drip.
[Copyright The Jiji Press, Ltd.]